Divine Aleru, Microbiome Signatures Research Coordinator

This study reveals that Fusobacterium animalis is linked to increased immune gene expression and microsatellite instability in CRC. It suggests Fusobacterium’s role in tumor progression, offering insights into potential biomarkers and therapeutic strategies for CRC patients.

This study uncovers the dual role of HmuF and FldH in Fusobacterium nucleatum’s anaerobic heme degradation, highlighting their functions in heme trafficking and reduction of anaerobilin, with implications for targeted therapeutic strategies.

What was studied? This study explored the role of Fusobacterium nucleatum’s outer membrane proteins, Fap2 and RadD, in inducing cell death in human lymphocytes. It focused on how these proteins, identified as part of the type Va autotransporter family, contribute to the bacterium’s virulence. The study examined the mechanisms by which Fap2 and RadD trigger […]

This study reveals Fn-Dps, a virulence factor from Fusobacterium nucleatum, as a key player in colorectal cancer metastasis, immune evasion, and erythrocyte disruption, highlighting its potential as a target for therapeutic intervention and a biomarker for CRC.

This review explores the role of Fusobacterium nucleatum in colorectal cancer, its impact on tumor progression, metastasis, immune modulation, and chemoresistance, and proposes potential strategies for CRC prevention and treatment.

This study identifies Fusobacterium nucleatum W1481 as a potential new subspecies, with unique genomic islands and antibiotic resistance mechanisms, highlighting its role in periodontal disease and potential for further clinical research.

This study explores how Fusobacterium nucleatum promotes chemoresistance in colorectal cancer by activating autophagy and altering microRNA expression, highlighting potential therapeutic avenues.

This study identifies Fusobacterium nucleatum as a significant pathogen in primary endodontic infections, strongly associated with clinical features like pain and swelling. The higher detection rate by PCR emphasizes the need for targeted treatments to eliminate this bacterium and improve endodontic outcomes.

What was studied? This study investigated the impact of Fusobacterium nucleatum’s FadA antigen on the competing endogenous RNA (ceRNA) network involving ANXA2 (Annexin A2) and its role in the progression of colorectal cancer (CRC) and adenomatous polyps (AP). Specifically, it examined how the FadA antigen contributes to the upregulation of ANXA2 through interactions with LINC00460 […]

This study shows that Fusobacterium nucleatum-derived extracellular vesicles activate the AIM2 inflammasome in intestinal epithelial cells, leading to pyroptosis and exacerbating ulcerative colitis. Targeting this pathway may offer a promising therapeutic strategy to alleviate UC progression.

This study explores how Fusobacterium nucleatum contributes to chemoresistance in colorectal cancer by activating the autophagy pathway through the downregulation of specific microRNAs, offering potential targets for improving chemotherapy outcomes.

This study identifies MegL as the major enzyme for H2S production in Fusobacterium nucleatum, crucial for bacterial fitness, antibiotic resistance, and virulence in preterm birth, offering potential therapeutic targets to manage F. nucleatum infections.

This study reveals a significant increase in penicillin-resistant Fusobacterium nucleatum in children due to beta-lactamase production, highlighting the role of antimicrobial exposure in the rise of resistance and the need for alternative treatment strategies in pediatric infections.

What was studied? This study investigated the production of beta-lactamase and antimicrobial susceptibility profiles of Fusobacterium nucleatum isolates from the oral microbiota of young children. The research aimed to identify the frequency of beta-lactamase production among different F. nucleatum subspecies, assess the associated resistance to antibiotics, and evaluate potential alternative treatments for infections caused by […]

This review discusses how Fusobacterium nucleatum adhesin RadD binds to CD147, promoting colorectal cancer proliferation. Targeting RadD may provide new therapeutic strategies for CRC treatment.

This study reveals that Fusobacterium nucleatum FadA promotes CRC through binding E-cadherin, activating beta-catenin signaling and inflammation. These findings suggest new diagnostic and therapeutic strategies targeting FadA to reduce CRC progression.

This study identifies the role of Fusobacterium nucleatum Fap2 in mediating bacterial enrichment in colorectal cancer by binding to tumor-expressed Gal-GalNAc. Targeting this interaction could reduce Fusobacterium’s potentiation of CRC, offering new therapeutic and diagnostic opportunities.

This review explores Fusobacterium nucleatum’s role as a transboundary pathogen in diseases like colorectal cancer and inflammatory bowel disease, highlighting its virulence factors, immune modulation, and complex microbial interactions. It offers insights into potential therapeutic strategies targeting this pathogen and its microbial networks.

This review discusses Fusobacterium nucleatum’s pivotal role in diseases like colorectal cancer and inflammatory bowel disease, emphasizing its pathogenic mechanisms, including immune evasion and tumor progression, and exploring novel diagnostic and therapeutic approaches targeting this bacterium.

This study explores the prevalence of Fusobacterium nucleatum in primary and secondary endodontic infections, highlighting its association with clinical symptoms like pain and swelling. PCR detection showed higher prevalence, emphasizing the pathogen’s role and the need for focused endodontic treatments.

Akkermansia muciniphila is a mucus-layer specialist that has shifted from “odd gut commensal” to one of the most mechanistically characterized next-generation probiotic candidates. First isolated from human feces using gastric mucin as the sole carbon and nitrogen source, it is adapted to life at the mucus–epithelium interface, where it converts host mucins into metabolites (notably acetate and propionate) that can feed other microbes and influence host physiology. Its genome encodes an unusually rich secretome for mucin foraging, dozens of predicted glycoside hydrolases, sulfatases, proteases, and sialidases, supporting stepwise dismantling of complex O-glycans and the mucin backbone.

This review shows that dietary polyphenols selectively increase Akkermansia muciniphila, improving gut barrier function and metabolic outcomes through microbiome-mediated mechanisms rather than direct antioxidant effects.

This review positions Akkermansia muciniphila as a key regulator of oxidative stress through mucin metabolism, bioactive proteins, and gut–organ signaling. Its clinical impact spans metabolic, inflammatory, and neurodegenerative conditions, with benefits strongly dependent on strain and host context.

What was reviewed? This systematic review evaluated how bioactive compounds, including dietary fibers, polyphenols, antioxidants, human milk oligosaccharides, and selected pharmaceuticals, influence the abundance and functional activity of Akkermansia muciniphila in the gut. Following PRISMA 2020 guidelines, the authors synthesized experimental evidence from 2004 to 2025 to clarify mechanisms through which these compounds modulate A. […]